

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board (the “**Board**”) of directors (the “**Directors**”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**”) is pleased to announce that the principal place of business of the Company in Hong Kong will be changed to Rooms 2101-2102, 21st Floor, Harbour Centre, 25 Harbour Road, Wanchai, Hong Kong with effect from 20 November 2012. The telephone and fax numbers of the Company remain unchanged.

By order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 19 November 2012

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Huang Chao, Mr. Xie Yunfeng, Mr. Wang Xianjun, Mr. Duan Wei, Mr. Bao Leyuan, Ms. Gao Shuping as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.